Pharming Group N.V.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands (Kingdom of the)
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Pharming is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Our key strengths include the following: - Sales growth of our commercialized asset. - Proven rare-disease commercialization capabilities. - Internal pipeline of product candidates. - Transgenic Production Platform Technology. - Data exclusivity, know-how and intellectual property.
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-12 07:44 |
Declaration of Voting Results & Voting Rights Announcements
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
|
Dutch | 182.9 KB | |
| 2025-06-12 07:44 |
Declaration of Voting Results & Voting Rights Announcements
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
|
English | 176.9 KB | |
| 2025-05-01 06:28 |
Inside Information Statement
Pharming Group announces the 2025 Annual General Meeting of Shareholders and th…
|
English | 182.9 KB | |
| 2025-04-23 09:44 |
Inside Information Statement
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as…
|
English | 296.9 KB | |
| 2025-04-03 07:26 |
Annual Report (ESEF)
Pharming Group N.V., Jaarlijkse financiële verslaggeving
|
English | 25.3 MB | |
| 2025-03-04 15:29 |
Inside Information Statement
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
|
Dutch | 224.7 KB | |
| 2025-03-04 15:29 |
Inside Information Statement
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
|
English | 224.4 KB | |
| 2025-02-21 07:38 |
Inside Information Statement
Pharming Technologies B.V. vergroot haar belang in Abliva AB (publ) naar 92,70 …
|
Dutch | 254.4 KB | |
| 2025-02-21 07:38 |
Takeover Announcement Report
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70…
|
English | 284.0 KB | |
| 2025-02-10 07:36 |
Inside Information Statement
Pharming Technologies B.V. declares unconditional and completes the recommended…
|
Dutch | 272.1 KB | |
| 2025-02-10 07:36 |
Takeover Announcement Report
Pharming Technologies B.V. declares unconditional and completes the recommended…
|
English | 250.1 KB | |
| 2025-01-21 18:16 |
General Meeting Notice
Pharming Group to convene Extraordinary General Meeting of Shareholders
|
Dutch | 174.3 KB | |
| 2025-01-21 18:16 |
Inside Information Statement
Pharming Group to convene Extraordinary General Meeting of Shareholders
|
English | 185.0 KB | |
| 2024-10-24 07:39 |
Earnings Release
Pharming Group reports third quarter 2024 financial results and provides busine…
|
Dutch | 568.1 KB | |
| 2024-10-24 07:39 |
Earnings Release
Pharming Group reports third quarter 2024 financial results and provides busine…
|
English | 461.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-03-24 | D.A. Jorn | Non-Executive member | Buy | 10,220 | 7,499.44 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 20,306 | 14,900.54 EUR |
| 2022-03-24 | P. Sekhri | Non-Executive member | Buy | 10,000 | 7,338.00 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Other | 2,363,455 | N/A |
| 2022-03-24 | P. Sekhri | Non-Executive member | Buy | 13,628 | 10,000.23 EUR |
| 2021-10-28 | D.A. Jorn | Non-Executive member | Buy | 7,241 | 7,500.08 EUR |
| 2021-10-28 | P. Sekhri | Non-Executive member | Buy | 9,655 | 10,000.46 EUR |
| 2021-08-05 | P. Sekhri | Non-Executive member | Buy | 19,879 | 20,590.27 EUR |
| 2021-08-05 | B. Yanni | Non-Executive member | Buy | 14,909 | 15,442.44 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |